Analysis of brentuximab vedotin for cutaneous and peripheral T-cell lymphoma, June 2024
Page last updated: 22 November 2024
Drug utilisation sub-committee (DUSC)
June 2024
Abstract
Purpose
At its February 2024 meeting, DUSC requested a review of brentuximab vedotin for CD30 positive cutaneous T-cell lymphoma (CTCL) and previously untreated CD30 positive peripheral T-cell lymphoma (PTCL).
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Brentuximab vedotin for CD30 positive CTCL was PBS listed on 1 April 2019. Brentuximab vedotin for previously untreated CD30 positive PTCL was PBS listed on 1 September 2021.
Data Source / methodology
Data extracted from the PBS and Authorities database maintained by Department of Health and Aged Care, processed by Services Australia were used for the analyses.
Key Findings
- In the 2022-23 financial year, there were 25 written authority approvals and 36 patients were supplied 207 prescriptions for brentuximab vedotin for CD30 positive CTCL.
- In the 2022-23 financial year, there were 113 written authority approvals and 113 patients were supplied 428 prescriptions for brentuximab vedotin for CD 30 positive PTCL. Utilisation of brentuximab vedotin for CD30 positive PTCL has been increasing over time.
- Utilisation of brentuximab vedotin for the treatment of PTCL was different from estimated.
- The median age of patients initiating treatment with PTCL was 62 years. The median age for males was 61 years, whereas for females this was 66 years.
